Maui Derm News: DecisionDx-SCC Improves Risk Stratification Among Patients With SCC Tumors on the Head or Neck When Combined With BWH Staging
The Dermatology Digest
JANUARY 20, 2025
Castle Biosciences, Inc.’s DecisionDx-SCC test improves risk stratification of patients with cutaneous squamous cell carcinoma (SCC) tumors located on the head or neck when the tests results are combined with Brigham and Womens Hospital (BWH) staging, new research shows. The new study was selected as a late breaker top five finalist for the best poster Akamai Award at the 2025 Maui Derm Hawaii meeting.
Let's personalize your content